血浆P-选择素在恶性肿瘤合并肺血栓栓塞症中的表达及临床应用分析

目的探究血浆P-选择素在恶性肿瘤合并肺血栓栓塞症(PTE)患者中的表达和临床应用。方法选择28例确诊为恶性肿瘤合并PTE患者作为恶性肿瘤合并PTE组,同期30例恶性肿瘤患者作为恶性肿瘤组, 28例下肢深静脉血栓形成(DVT)患者作为DVT组, 30例PTE患者作为PTE组30例。采用酶联免疫吸附剂测定(ELISA)法测定各组患者的P-选择素表达水平,并进行比较。结果恶性肿瘤合并PTE组患者P-选择素表达水平(71.25±51.06)ng/ml明显高于恶性肿瘤组的(42.98±43.08)、DVT组的(47.28±25.12)ng/ml、PTE组的(50.13±25.06)ng/ml,差异具有统计学意义(P<0.05);恶性肿瘤组、DVT组、PTE组患者P-选择素表达水平两两比较差异无统计学意义(P>0.05)。恶性肿瘤合并PTE组、恶性肿瘤组淋巴结转移患者的P-选择素表达水平显著高于同组淋巴结未转移患者,差异具有统计学意义(P<0.05);恶性肿瘤合并PTE组、PTE组中高危、高危患者均显著高于同组低危、中低危患者,差异具有统计学意义(P<0.05)。结论血浆P-选择素可以作为恶性肿瘤合并PTE的诊断因子,指导PTE临床分级,且可能和淋巴结转移有关。

Analysis of expression and clinical application of plasma P-selectin in malignant tumor complicated by pulmonary thromboembolism

Objective To investigate the expression and clinical application of plasma P-selectin in patients with malignant tumor and pulmonary thromboembolism(PTE). Methods There were 28 patients with malignant tumor and PTE selected as malignant tumor and PTE group, 30 patients with malignant tumor as malignant tumor group, 28 patients with lower extremity deep vein thrombosis(DVT) as DVT group and 30 patients with PTE as PTE group. Enzyme-linked immunosorbent assay(ELISA) was used to determine the expression of P-selectin in each group of patients, and then compared. Results The P-selectin expression level of malignant tumor and PTE group was(71.25±51.06)ng/ml, which was obviously higher than malignant tumor group of(42.98±43.08), DVT group of(47.28±25.12) ng/ml and PTE group of(50.13±25.06) ng/ml, and the difference was statistically significant(P<0.05). There was no statistically significant difference in P-selectin expression level between every two groups of malignant tumor group, DVT group and PTE group(P>0.05). In malignant tumor and PTE group and malignant tumor group, the expression level of P-selectin in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis of the same group, and the difference was statistically significant(P<0.05). Patients of middle-high risk and high risk in malignant tumor and PTE group and PTE group were significantly more than patients of low-risk and middle-low risk in the same group, and the difference was statistically significant(P<0.05). Conclusion Plasma P-selectin can be used as a diagnostic factor for malignant tumors complicated by PTE, guiding the clinical classification of PTE, and may be related to lymph node metastasis.